-Visit OBiO Tech booth #1644 at
American Society of Gene & Cell
Therapy in Maryland, USA
SHANGHAI, April 28, 2024 /PRNewswire/ -- OBiO Technology
(Shanghai) Corp., Ltd. (OBiO,
688238.SH), a world leading contract development and manufacturing
organization for cell and gene therapy, will showcase at
American Society of Gene & Cell Therapy in Maryland,
USA from May 7th to 11th. 9 posters
will be presented at American Society of Gene & Cell
Therapy.
Among these presentations are three self-developed patented
achievements, four notable advancements in process optimization,
and two cutting-edge technology introductions.
These milestones exemplify OBiO Technology's significant strides
in the gene therapy domain, enhancing vector yield and efficiency,
refining therapeutic processes, and driving down production
costs.
The innovative solutions offered by OBiO Technology provide
dependable and cost-effective production methods for gene
therapy, propelling forward clinical projects in gene and cell
therapy.
OBiO Technology's experts are ready to share how their
comprehensive viral vector platform accelerates development
timelines, de-risks manufacturing, and provides the performance and
product quality needed for your success, with a lower cost.
"We are delighted to continue our legacy of excellence at the
ASGCT conference! OBiO Technology will participate with utmost
enthusiasm and innovative prowess, showcasing our latest
achievements in gene and cell therapy." said Javier Jia Guo, Ph.D., Chief Executive Officer
of OBiO Technology. "Our nine presentations, featuring
self-developed patented achievements, process optimization
breakthroughs, and technology introductions, epitomize our
commitment to relentless innovation and collaborative
problem-solving. They also underscore our significant progress in
enhancing yield efficiency, streamlining production processes, and
driving cost efficiencies. OBiO Technology remains steadfast in its
forward-looking technological layout and continuous improvement of
service capabilities, contributing to the rapid advancement of the
gene and cell therapy industry."
About OBiO Technology
OBiO Technology leads the way in gene and cell therapy as a
pioneering Contract Research Organization (CRO) and Contract
Development and Manufacturing Organization (CDMO), dedicated to
providing comprehensive solutions.
- OBiO Technology's state-of-the-art 830,000 sq.ft facility
ensures global supply excellence.
- Specializing in vectorology studies, functional genomics, and
process and analytics development, OBiO Technology ensure
Investigational New Drug (IND) readiness and support all phases of
clinical and commercial manufacturing.
- Guided by mission to "Enable Gene Therapy for Better Lives,"
OBiO Technology prioritize delivering top-tier services
worldwide.
- From laboratory to clinic, OBiO Technology continuously advance
your products, making a positive impact on populations
worldwide.
- OBiO Technology's unwavering commitment ensures the delivery of
high-quality CDMO services across the preclinical, IND, clinical,
and commercial stages.
- OBiO Technology's expertise spans plasmids, mRNA, AAV, LVV, Ad
viral vectors, cell therapy (CAR-T, NK, Treg), as well as
cutting-edge technologies like inducible viral vector packaging,
ultralow endotoxin processes, and tissue-specific AAV
variants.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/obio-technology-will-showcase-at-american-society-of-gene--cell-therapy-302129370.html
SOURCE OBiO Technology (Shanghai) Corp., Ltd.